**Background**

Both diabetes and immunosuppressive treatment predispose children to plaque-related gingivitis and oral yeast infections [1-12]. Both diseases present a number of factors promoting bacterial and fungal infections. Reduced salivary flow and modified salivary composition might occur in uncompensated diabetes [13]. Neutrophil activity and cell-mediated immunity are impaired. Patients with diabetes are even considered to present a modified oral bacterial flora, which might promote fungal infections [14,15]. An impaired cellular response is also related to long-term immunosuppressive treatment in Nephrotic syndrome. The syndrome (NS) is a clinical condition with a proteinuria level exceeding the body's compensating abilities (protein loss over 50 mg/kg/day). Proteinuria results in hypo- and dysproteinenaemia, hyperlipidaemia, and modifications in immunoglobulin composition (including decreased IgG levels), which additionally impair the body's immunity [16].

Candida spp. often colonises the oral cavity without presenting any lesions. However, candidiasis symptoms also occur in an impaired defence mechanism and fungus-
host imbalance [17-19]. Yeast-like fungi also frequently found in non-candidiasis related oral mucosal lesions [20,21]. They may cause gingivitis, developing independently out of plaque, such as linear gingival erythema (LGE) manifesting as gingival margin erythema. It may also sometimes develop from the attached related gingiva, and manifest as spontaneous bleeding [4,22].

Yeast-like fungi might also lead to periodontitis. Candida albicans has been isolated from periodontal pockets and root canals [23-25]. The production of inflammatory cytokines is said to be more important in the presence of C. albicans as a response to cellular wall lipopolysaccharide activity, and thus increasing the severity of periodontitis [26,27]. Candida albicans has also been found to facilitate the P. gingivalis invasion into epithelial cells and fibroblasts [28].

Detection of yeast-like fungi does not prove their role in lesion formation. It is crucial to determine their invasive capacity, reflected in the activity of hydrolytic enzymes produced by yeast-like fungi, including alpha–glucosidase (E16) and β-N-acetylglucosaminidase (E18) [29-33]. E16 and E18 were proven to inhibit neutrophil migration to the source of the infection [33]. Beta-N-acetylglucosaminidase has also been found to induce filamentation, i.e. it exerts its impact on the formation of ‘germ tubes’ [32]. An important activity of these enzymes at the lesion site might reflect the pathogenic role of yeast-like fungi.

Children and teenagers with diabetes and with NS undergoing immunosuppressive treatment are predisposed to gingivitis. Candida spp. has often colonises the oral cavity, and candidiasis occurs more frequently than in the general healthy population. In the previous study, Candida spp. was isolated in 45.4% of children with nephrotic syndrome undergoing immunosuppressive treatment, and in 14.8% of those with type 1 diabetes. Oral candidiasis was diagnosed in 13.3% of patients with NS and in 11.1% of those with uncompensated diabetes [4]. However, even though yeast-like fungi might intensify the infection, their impact on the condition of the gingiva in those diseases has not been assessed.

The present study has assessed the impact of Candida spp. and the general factors related to the disease or its treatment in the severe plaque-related gingivitis in children and adolescents with diabetes or Nephrotic syndrome.

**Methods**

The study was conducted using 96 subjects: 32 with NS, 35 with type 1 diabetes, and 29 that were generally healthy (control group) (Table 1). The inclusion criteria were: age from between 3 to 18 years and a written informed consent of the child and/or their parent/guardian, as well as:

- In the NS group: no treatment with drugs other than those used in the treatment of NS, no chronic disease other than kidney disease
- In the diabetes group: no chronic disease other than diabetes or drug therapy
- In the control group: no chronic disease or drug therapy

The exclusion criteria included: tobacco smoking, orthodontic appliances or dental prosthesis use, antifungal treatments, and antibiotic therapy at the time of qualification for the study and during the three previous weeks. The NS and diabetes groups included patients referred to the dentists by paediatricians and those who presented themselves for a check up at a nephrology or diabetes clinic. Patients presenting for the first time at the Department of Paediatric Dentistry were qualified to participate in the control group.

The Warsaw Medical University Committee for Ethics approved the study. The study was prospective and included a general medical and oral examination (clinical

| Group                     | Number of patients (girls/boys) | Age in years range (mean ± SD) | Biochemical parameter      | Mean ± SD      |
|---------------------------|---------------------------------|--------------------------------|---------------------------|----------------|
| Control group             | 29 (10/19)                      | 3-17.1 (11.52 ± 4.01)          | -                         | -              |
| Nephrotic syndrome        | 32 (13/19)                      | 3-18 (10.05 ± 4.8)             | Proteinuria (mg/kg/day)    | 73.2 ± 104.24  |
|                           |                                 |                                | Albumin (g/dL)             | 3.54 ± 0.84    |
|                           |                                 |                                | Total protein (g/dL)       | 6.4 ± 1.17     |
|                           |                                 |                                | Haemoglobin (g%)           | 13.73 ± 1.46   |
|                           |                                 |                                | Hematocrit (%)             | 41.74 ± 4.37   |
|                           |                                 |                                | Leukocyte count (x10³/mm³)| 9.8 ± 3.16     |
|                           |                                 |                                | Cholesterol (mg/dL)        | 262.29 ± 127.33|
|                           |                                 |                                | Triglycerides (mg/dL)      | 176.33 ± 165.23|
| Type 1 diabetes           | 35 (17/18)                      | 6-17.9 (13.24 ± 2.64)          | Blood glucose level (mg/dL)| 173.94 ± 70.3  |
|                           |                                 |                                | HbA1c (%)                  | 8.93 ± 2.16    |
assessment and laboratory tests) and a medical history review. The oral examination was performed following the general medical examination (clinical and sampling for the scheduled laboratory tests) on the same or following day. Just prior to the clinical the obtained swabs were sent for mycological testing. The dentists were only aware of the patient’s disease (diabetes or Nephrotic syndrome). They did not know the general medical details of the NS and diabetes patients, including the main disease course and treatment plan, neither of the occurrence of other diseases. The statistical analysis of the obtained results was also performed.

**General medical examination**

BMI was calculated in kg/m² for all clients, and adjusted to their age and gender to provide a BMI standard deviation score (SDS) [34].

**NS group**

Information on the NS patient treatment was obtained from available medical records, including that on the administered drugs with dosage and treatment duration. Laboratory blood tests included total protein (reference range 6–8 g/dL), albumin (reference range 3.7–5.6 g/dL), creatinine, cholesterol, triglycerides, haemoglobin, haematocrit (reference ranges, depending on age), and white blood cell count, measured with standard laboratory methods. A 24-hour urinary protein excretion was measured using turbidimetry.

**Diabetes group**

Information on diabetes duration was obtained from the available medical records. Laboratory data, including measurements of glycated haemoglobin – HbA1c (with D-10 high-performance liquid chromatography), blood glucose levels (with a testing strip using a standard glucose metre), cholesterol and triglycerides, using standard laboratory methods, were collected. The criteria for compensated diabetes were: HbA1c <7% – good, 7–8% – average, and >8% – bad.

**Oral assessment included the oral mucosa, general hygiene level, and gingiva**

Oral candidiasis was assessed according to the World Health Organisation guidelines [35]. The oral hygiene score was based on the Silness and Löe plaque index (PLI). Plaque deposits were assessed in the cervical area of six teeth: 16, 12, 24, 36, 32, 44 (55, 51, 63, 75, 71, 83 in deciduous teeth), according to the criteria: 0 – no plaque, 1 – a film of plaque visible on probing the gingival margin, 2 – visible accumulation of deposits, 3 – abundance of soft matter within the gingival pocket [36]. The index is the quotient of the sum of the values obtained for all studied tooth surfaces (medial, distal, buccal, and lingual) and the number of examined areas. The gingival score was based on the Silness and Löe Gingival Index (GI). The gingival tissues were assessed around the same teeth according to the following criteria:

0. No inflammation – healthy gingiva
1. Mild inflammation – slight change in colour and in tissue structure; no bleeding on probing
2. Moderate inflammation – visible glazing, redness, oedema, and hypertrophy; bleeding on pressing or probing,
3. Severe inflammation – marked redness and hypertrophy; tendency towards spontaneous bleeding; ulceration.

The GI is the quotient of the sum of the values for all gingival surfaces of the scored teeth and the number of scored surfaces [36]. Gingivitis severity was scored as follows: 0.1–1.0: mild inflammation; 1.1–2.0: moderate inflammation, and 2.1–3.0: severe inflammation. Linear gingival erythema, gingival overgrowth and pockets deeper than 4 mm (with the use of a calibrated periodontal probe) were also reported.

**Microbiological examination**

Oral swabs from the patients were cultured on Sabouraud agar. After a 24–72 h incubation at 30°C, the following items were assessed:

- Species identification with commercial tests ID 32 C, performed with automated ATB Expression [20],
- Assessment of enzyme activity: valine arylamidase (E7), α-glucosidase (E16), β-N-acetyl-glucosaminidase (E18), performed with API 20 C AUX and API ZYM tests [37,38].

The API-ZYM micro test using 20 micro-vials included 19 substrates to detect 19 hydrolytic enzymes. The first micro-vial served as a negative control. The second contained a substrate for alkaline phosphatase (E2). Micro-vials 3–5 contained substrates for esterase (C4), esterase lipase (C8), and lipase (C14). Micro-vials 6–10 contained substrates for proteases. Finally, micro-vials 13–20 contained substrates for glucosidases. The micro-vials were filled with 65 μL of urine and incubated for 4–4.5 h at 37°C. Following the incubation, one drop of reagent (ZYM A or ZYM B) was added to each micro-vial and the intensity of the colour reaction was read after five minutes, using special tables provided with the kit, with scores from 0 to 5, where 0 corresponded to a negative reaction (0 nmol), 1 to 5 nmol, 2 to 10 nmol, 3 to 20 nmol, 4 to 30 nmol, and 5 to a reaction with maximum intensity, i.e. 40 nmol. Three Candida albicans isolates, out of eight...
cultured strains, were used to test for potentially identical enzymatic profiles.

**Statistical analysis**
For all variables, the mean values and standard deviations (SD) or proportions were calculated. The t-test was used to compare means in the examined groups, and the chi-squared test was used to compare fractions. Correlations between the selected variables were assessed using the Kendall rank correlation coefficient (significance level P < 0.05). The statistical analysis was performed using the Statistica 10.0 software. Correlations between the GI and selected properties were calculated jointly for all groups to determine the ratio of ill and healthy subjects in the population. Correlations were also calculated separately for each group of ill children under study, to check whether the correlation was similar to the one in the entire population of healthy and ill subjects. It was necessary to double-check them in order to avoid the Simpson’s paradox, i.e. the effect of apparent correlations resulting from important disparities among the assessed groups. Moreover, a multiple regression analysis was used to assess the simultaneous effect of many independent variables on the GI. Partial standardised regression coefficients were presented.

**Results**

**Medical status**
The BMI in the NS group ranged between 14.36 and 41.0 kg/m² and the BMI SDS was between −0.9 and 3.3 (mean BMI: 22.1 ± 6.06 kg/m²). In the diabetes group, the BMI ranged between 14 and 32 kg/m², and the BMI SDS between −1.3 and 2.5 (mean BMI: 20.07 ± 3.52 kg/m²). In the control group, the BMI ranged between 12.2 and 31 kg/m² for the BMI, and between −2.2 and 2.3 for the BMI SDS (mean BMI: 19.51 ± 4.12 kg/m²).

In the NS group, disease duration ranged between 0.5 and 15.67 years (mean duration: 5.06 ± 4.95 years). Thirty patients with NS received immunosuppressive treatment, including single drug immunosuppression in 14 patients (with corticosteroids [CS]), immunosuppression with two drugs in 11 patients (in seven patients, CS and cyclosporin A [CsA], and in four patients, CS and azathioprine), and immunosuppression with three drugs in five patients (with CS, CsA and mycophenolate mofetil [MMF]). Corticosteroids, used by 29 patients (mean dose: 33.25 ± 19.9 mg/day, mean treatment duration: 3.99 ± 4.45 years), and cyclosporin A was used in 10 patients (mean dose: 134.54 ± 48.0 mg/day, mean treatment duration 3.88 ± 2.95 years), were the most commonly administered drugs. Proteinuria occurred in 23 patients with NS (71.87%), hypoalbuminemia in 23 patients (71.87%), decreased serum total protein levels in 10 patients (31.25%), decreased haemoglobin levels in four patients (12.5%), increased haematocrit in 16 patients (50.0%), hyperleukocytosis in 15 patients (46.87%), elevated cholesterol levels in 22 patients (68.75%), and elevated triglyceride levels in 14 patients (43.75%).

In patients with diabetes, the duration of the disease ranged between 0.1 and 9.58 years (mean duration: 2.82 ± 2.5 years). Patients with diabetes received from 0.1 to 1.3 units of insulin/kg of body mass (mean 0.76 ± 0.29). Blood sugar level ranged between 69 and 300 mg/dl. In 17 patients (48.57%), the Hb1c level was higher than 8% (uncompensated diabetes) and in four patients (11.4%), it was lower than 7%. Hypercholesterolemia occurred in seven patients (20.0%) and higher blood triglyceride levels in five patients (14.28%). Table 1 presents the mean values of the evaluated biochemical parameters in patients with NS, as well as the levels of glycated haemoglobin (HbA1c).

**Oral cavity**
_Candida spp_ were frequently found in the oral cavity of the controls (41.37% subjects), and less often in patients with NS (34.37%, all under immunosuppressive treatment) and those with diabetes (22.85%) (statistically insignificant differences). Only _Candida albicans_ was isolated. Table 2 presents oral _Candida_ prevalence in the respective groups and the activity of the Candida enzymes obtained from the oral cavity, including valine arylamidase (E7), alpha-glucosidase (E16), and N-acetyl-beta-glucosaminidase (E18). A considerably higher level of E16 activity was discovered only on comparing the NS group to the control group (Table 2). Oral candidiasis was diagnosed in three patients with NS (9.37%) and in four with diabetes (11.4%). Erythematous candidiasis, pseudomembranous candidiasis with associated median rhomboid glossitis, and angular cheilitis were resident in patients with NS. Erythematous candidiasis (1), angular cheilitis (3), and pseudomembranous candidiasis with associated median rhomboid glossitis were noted in patients with diabetes.

Gingivitis was more frequent in patients with diabetes (80%) and with NS (62.5%) than in the controls (37.93%). There was a statistically significant difference only between D1 and C (Table 3). No patient presented severe gingivitis or periodontitis. Nine NS patients presented periodontal pockets deeper than 4 mm in a single tooth, caused by cyclosporine-associated gingival hyperplasia. Moderate gingivitis was diagnosed significantly more often in the NS group. Patients with both diabetes and NS presented significantly higher GIs than did the controls. Gingivitis was related to plaque presence in all the study groups. (ab. 3).

The Kendall rank correlation coefficient for NS and controls, as well as for D1 and controls, also indicated a correlation between GI and yeast enzyme activity (E7, E16, and E18). In diabetes, the occurrence of only yeasts
in the oral cavity was crucial (Table 4). The individual assessment of the respective groups indicated that intensified gingivitis in the NS patients Nephrotic syndrome was related only to a high E18 activity. Immunosuppressive treatment, especially with more than one drug, disease duration, the BMI and BMI SDS, a higher blood cholesterol level (mg/dL), and age had a crucial impact on gingivitis severity in patients with NS. Additionally, the duration of glucocorticoid treatment (significant Kendall rank correlation coefficient: 0.258), and the dosage and duration of CsA treatment (significant Kendall rank correlation coefficient: 0.461, 0.407) were also correlated with the GI. The assessment in D1 and controls indicated a correlation between GI and age, as well as disease duration and elevated blood glucose levels. The correlation coefficient was statistically and significantly negative for HbA1c <7%, and positive for HbA1c > 8% (Table 4). A similar assessment only in the diabetes group confirmed a negative correlation for HbA1c <7%.

Discussion

There are many publications associating frequent gingivitis and oral candidiasis with impaired immune defence mechanisms, such as in organ recipients receiving immunosuppressive treatment, cancer patients receiving cytotoxic treatment, patients with AIDS, or patients with diabetes [1-12]. In the present study, candidiasis only occurred in children with NS or diabetes. In those groups, gingivitis was more frequent and showed a more severe course compared to that in the generally healthy

### Table 2 Candida spp. prevalence and activity of Candida enzymes isolated from the oral cavity in patients from the control group (C), with Nephrotic syndrome (NS), and with type 1 diabetes (D1)

| Group | Candida spp. | Activity of Candida enzymes isolated from oral cavity |
|-------|--------------|------------------------------------------------------|
|       | Code E7 or E16 or E18 | Code E7 | Code E16 | Code E18 |
|       | 1-5 | 5 | n | 1-5 | 5 | n | 1-5 | 5 | n |
| NS    | 11/34.37 | 11/34.37 | 8/25.00 | 11 | 1 | 9 | 5 | 10 | 6 |
| D1    | 8/22.86 | 7/20.0 | 6/17.14 | 7 | 0 | 7 | 4 | 9 | 4 |
| C     | 12/41.37 | 10/34.48 | 2/6.89 | 11 | 0 | 10 | 0 | 10 | 2 |

P-value - chi-squared test

NS vs C 0.573 0.993 0.057 0.773 0.337 0.592 0.026* 0.788 0.171

D1 vs C 0.111 0.192 0.217 0.112 1.000 0.192 0.060 0.445 0.536

*significantly different at P < 0.05.

### Table 3 Oral hygiene (PLI) and gingivae condition (GI) in patients from groups: with nephrotic syndrome (NS), with diabetes (D1), and control (C)

| Parameter | NS | D1 | C | P-value |
|-----------|----|----|----|---------|
| PLI mean ± SD | 0.98 ± 0.61 | 1.02 ± 0.51 | 0.53 ± 0.69 | NS vs C 0.011* |
| GI       | 0.62 ± 0.69 | 0.47 ± 0.38 | 0.24 ± 0.42 | NS vs C 0.014* |
| GI ≥ 0.1 n/% | 20/62.5 | 28/80.0 | 11/37.93 | NS vs C 0.055 |
| GI ≥ 1.1 | 10/31.25 | 4/11.43 | 1/3.45 | NS vs C 0.005* |
| Correlation between PLI and GI | 0.482* (P < 0.001) | 0.633* (P < 0.001) | 0.670* (P < 0.001) | - |

*significantly different at P < 0.05; the t-test was used to compare means, and the chi-squared test to compare fractions.
children. Dental plaque was the main cause behind gingivitis. The present study confirmed a correlation between GI, PLI, and the child and adolescent age. Romero et al. also established that GI increased with age in children, even though PLI decreased [39].

Treatment of gingivitis consisting in removal of the dental plaque and factors contributing to its retention may be not successful in patients with systemic disease. Systemic diseases are usually associated with diverse disorders which may favourably affect the development of gingivitis or increase its severity accompanied by diverse disorders which may favourably affect the presence or development of gingivitis. Among them, there may be nonmodifiable and modifiable factors whose influence (=activity) may be nonmodifiable and modifiable factors, whose influence (activity) may be an may decrease their effect and consequently achieve better more effective results.

The present study, assessing the impact of the respective factors, including the occurrence if Candida spp. in the oral cavity, and the systemic disorders in diabetes and NS, selects factors associated with the disease or its treatment influencing severity of gingivitis that may intensify development. The study draws attention to considering antifungal treatment as element of gingivitis therapy. It accentuates the significance of maintaining a proper body weight. The assessment of the simultaneous impact of factors (multiple regression) was not statistically significant for most of them. It was caused of their mutual correlations. However, the coefficients of determination ($R^2$) indicated a significant impact of the assessed factors on GI (Table 4).

Gingiva in children with NS has not been previously assessed, however, the observation of patients with kidney or liver transplants that are under immunosuppressive treatments indicated a correlation between gingivitis severity and GI [20,21]. Other authors concluded the same in diabetes, independent of the definition of periodontal disease [12,40-42]. Lalla et al., examining 83 patients with diabetes and 80 generally healthy children and adolescents, confirmed that children with diabetes presented significantly more dental plaque and a higher

| Parameters                                      | NS and C   | Only NS | D1 and C | Only D1 |
|------------------------------------------------|------------|---------|----------|---------|
| Candida spp. occurrence                        | 0.046      | 0.082   | 0.180*   | 0.243*  |
| Enzymatic activity of Candida spp. isolated    | 0.222*     | 0.098   | 0.272*   | -       |
| from the oral cavity                           |             |         | 0.211    | -       |
| code E7                                        | -0.010     | -0.060  | -0.173   | -0.377* |
| code E16                                       | 0.215*     | 0.070   | 0.316*   | 0.417*  |
| code E18                                       | 0.094      | 0.025   | 0.283*   | 0.424   |
| Immunosuppressive treatment                    | 0.205*     | 0.136   | -        | -       |
| >1 drug                                        | 0.359*     | 0.388*  | 0.207    | 0.128   |
| Elevated cholesterol level                     | 0.219*     | 0.201   | 0.038    | -0.137  |
| Elevated triglyceride level                    | 0.166      | 0.133   | 0.115    | -0.061  |
| HbA1c                                          | -         | -       | 0.300*   | 0.207   |
| <7%                                            | -         | -       | -0.328*  | -0.282  |
| >8%                                            | -         | -       | 0.255*   | 0.189   |
| Blood glucose level (elevated)                 | -         | -       | 0.187*   | -0.098  |
| BMI                                            | 0.329*     | 0.302*  | 0.141    | -0.105  |
| BMI in SDS                                     | 0.240*     | 0.268*  | 0.030    | -0.067  |
| Disease duration                               | 0.226*     | 0.256*  | 0.200*   | -0.041  |
| Age                                            | 0.195*     | 0.151   | 0.201*   | -0.052  |
| Sex                                            | -0.006     | 0.149   | -0.038   | 0.131   |
| $R^2$ – coefficient of determination           | 0.468      | 0.662   | 0.309    | 0.520   |

*Statistically significant correlation (P < 0.05).
GI than did the nondiabetic controls (plaque index 1.2 vs. 1.1, gingival index 1.2 vs. 1.1, respectively) [12]. Lalla et al. used three definitions of periodontal disease: attachment loss, gingival bleeding, or both. Their regression analysis indicated that diabetes presented a statistically significant correlation with periodontitis, even in the 6- to 11-year-old group of patients with diabetes. However, they did not find any correlation between the inflammation of periodontal tissues and the degree of diabetes compensation (mean HbA1C) and lipid profiles [12]. This is contrary to the present study and to earlier evidence suggesting improper management of diabetes and the associated metabolic disorders predisposed to more severe periodontitis [43]. Saeas Busato et al. confirmed, in their study on young patients with diabetes, with the results based on the Community Periodontal Index (CPI), the negative impact of improper diabetes management. Adolescents with poor metabolic control presented a higher CPI than did the group with good metabolic control (2.0 and 1.4, respectively) [42]. Lalla et al. noticed a correlation between periodontitis in diabetes and BMI, which was also confirmed by others authors that used adults in their studies [12,44,45]. The results of the present study also suggest a correlation with gingivitis severity. However, it was only evident for all of the patients together, independently of their general health, and in controls and NS.

The correlation between GI and high cholesterol levels in children with nephrotic syndrome is worth noting. A higher level of cholesterol and triglycerides occurs in nephrotic syndrome relapse and can be upheld for a long period of time, even in remission [46]. Hyperlipidaemia in remission, and especially total cholesterol level in the serum, is considered a predictor of idiopathic nephrotic syndrome relapse in children [47]. Patients with diabetes also present higher cholesterol and triglyceride (TRG) levels, even if the blood glucose level was well-managed. Periodontitis-induced bacteraemia is also implied increased serum pro-inflammatory cytokine levels, leading to hyperlipidaemia [11]. Although the present study did not confirm correlations between the GI and lipid profile disorders in diabetes, it is necessary to continue studying both diseases in larger patient groups.

There many factors promoting periodontitis in diabetes (such as alterations in host response, collagen metabolism, vasculature, gingival crevicular fluid, and heredity patterns) and in those receiving immunosuppressive treatment (drugs, dosage, and treatment duration). However, the correlation between gingivitis severity and yeast-like fungi in the oral cavity was not assessed, even if fungal infections occurred more often in these patients. In the present study, yeast-like fungi less frequently colonised the oral cavity of patients with nephrotic syndrome or diabetes, compared to the generally healthy participants, but Candida spp. more often led to candidiasis. There was no difference between the enzymatic activity of the strains isolated from the oral cavity in patients with NS and diabetes and that of the controls. Plomer-Niezgoda et al. showed different Candida enzymatic biotypes, according to the Williamson classification, in patients under immunosuppressive therapy (biotypes C and B) and healthy subjects (biotypes A and B), but both groups presented E7, E16, and E18 activity [48]. It is also interesting to note that the present study established a correlation between gingivitis and the local Candida enzyme oral activity, including valine arylamidase (E7), alpha-glucosidase (E16), and N-acetyl-beta-glucosaminidase (E18). In Kurnatowska and Kurnatowski’s study, 40% of Candida albicans strains isolated in gingivitis were biotype F, according to the Williamson classification, i.e characterised by esterase (E3), E7, naphthol-AS-BI-phosphohydrolase (E12), and E16 activity, 15% were biotype A (also presenting E18 activity), 5% biotype B (E3, E12, E16, and E18 activity), 5% biotype E (E3, E7, and E12 activity), and 5% were biotype G (E3, E12, and E16 activity). The remaining strains were classified as biotypes defined by those authors, including 15% as biotype N (E3 and E18 activity), 5% as biotype I (E18 activity only), and 5% as biotype K (E3, E7, and E16 activity) [49]. These results do not only confirm a correlation between gingivitis and E7, E16, and E18 activity, but also indicate that the N-acetyl-beta-glucosaminidase activity is related to inflammation severity. Considering the role of E18 in the formation of invasive germ tubes, these results may confirm the etiopathogenetic role of Candida in the development of gingivitis.

Conclusions

The main cause of gingivitis is poor oral hygiene. There is most likely a correlation between gingivitis severity and age, BMI and lipid disorders. Candida spp., residing in the oral cavity of patients with uncompensated diabetes or those receiving multi-drug immunosuppressive treatment, may potentiate the severity of plaque-related gingivitis.

Abbreviations

BMI: Body Mass Index; BMI/SDS: BMI standard deviation score; PLI: Sillness and Löe plaque index; GI: Sillness and Löe Gingival Index; HbA1c: Glycated haemoglobin; NS: Nephrotic Syndrome; LGE: Linear Gingival Erythema; E16: Alpha-glucosidase; E18: β-N-acetylglucosaminidase; E7: valine arylamidase; E2: Alkaline phosphatase; C4: Micro-vascular 3–5 contained substrates for esterase; C8: Esterase lipase; C14: Lipase; SD: Standard deviation; C5: Corticosteroids; C2A: Cyclosporine; MMF: Mycophenolate mofetil; AIDS: Acquired Immune Deficiency Syndrome; CPI: Community Periodontal Index; TRG: Cholesterol and Triglyceride; E3: Esterase; E12: Naphthol-AS-Bl-phosphohydrolase.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

DOK – came up with the study idea, carried out the clinical studies, took part in the sequence alignment, drafted the manuscript, read and approved the final manuscript. BF – carried out the clinical studies, took part in the
drafting of the manuscript, read and approved the final manuscript. MD – carried out the clinical studies, took part in the drafting of the manuscript, read and approved the final manuscript. MPT – carried out the clinical studies, took part in the drafting of the manuscript, read and approved the final manuscript. GM – carried out the clinical studies, took part in the drafting of the manuscript, read and approved the final manuscript. IR – carried out the clinical studies, took part in the drafting of the manuscript, read and approved the final manuscript. ESK – carried out the microbiological research, took part in the drafting of the manuscript, read and approved the final manuscript. DG – took part in sequence alignment and study design and performed the statistical analysis. AK – carried out the clinical studies, took part in the drafting of the manuscript, read and approved the final manuscript. AP – carried out the clinical studies, took part in the drafting of the manuscript, read and approved the final manuscript. All authors read and approved the final manuscript.

Author details
1. Department of Paediatric Dentistry, Medical University of Warsaw, 18 Miodowa St, 00-246 Warsaw, Poland. 2. Department of Paediatric Endocrinology, Medical University of Warsaw, Warsaw, Poland. 3. Department of Dental Medical Microbiology, Medical University of Warsaw, Warsaw, Poland. 4. Department of Paediatric Nephrology, Medical University of Warsaw, Warsaw, Poland. 5. Department of Experimental Statistics and Bioinformatics, Warsaw University of Life Sciences, Warsaw, Poland.

Received: 11 November 2014 Accepted: 28 April 2015

References
1. Ship JA. Diabetes and oral health. An overview. J Am Dent Assoc. 2003;134:4–10.
2. Pedersen AML. Diabetes mellitus and related oral manifestations. Oral Biosci Med. 2004;1:229–48.
3. Guggenheimer J, Moore PA, Rossie K, Myers D, Mongelluzzo MB, Block HM, et al. Insulin-dependent diabetes mellitus and oral soft tissue pathologies. II. Prevalence and characteristics of Candida and Candida lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;89(5):570–60.
4. Soysa NS, Samaranayake LP, Ellepola AN. Diabetes mellitus as a contributory factor in oral candidiasis. Diabet Med. 2006;23(5):455–9.
5. Olczak-Kowalczyk D, Roszkowska-Slami M, Paliych-Tomaszewska M, Djikobowska Mi, Sooboda-Kopc K, Pyrzel B, et al. Candida spp. in oral cavity of children with immunodeficiencies. In: Contreras F, Fuentes P, editors. Immunology and Immunopathology of Oral and Dental Microorganisms. 2009. p. 137–46.
6. Olczak-Kowalczyk D, Pawlowska J, Garcewicz B, Smierska E, Grenda R, Syczewska M, et al. Oral candidiasis in immunosuppressed children and young adults after liver or kidney transplantation. Pediatr Dent. 2010;12:189–94.
7. Al Mohaya MA, Darwaizh A, Al Khudair W. Oral fungal colonization and oral candidiasis in renal transplant patients: the relationship to Miswak use. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93(4):455–60.
8. Dongari-Bagtzoglou A, Divvitie P, Ioannidou E, Shaqman M, Hull D, Burleson J. Oral Candida infection and colonization in solid organ transplant recipients. Oral Microbiol Immunol. 2000;15(4):294–59.
9. Olczak-Kowalczyk D. Gingival disease in development age patients after solid organ transplantation (liver or kidney). Nowa Stomatol. 2001;1:21–4.
10. Olczak-Kowalczyk D, Pawlowska J. Gingival status in patients on cyclosporine A or tacrolimus immunosuppression following kidney or liver transplant. Przegl Stomatol. 2009;62(2):149–62 [In polish].
11. Iacobini AM. Periodontitis and diabetes interrelationships: role of the inflammatory mediator. Ann Periodontol. 2001;6(1):25–37.
12. Lalla E, Cheng B, Lai S, Tucker S, Greenberg E, Goland R, et al. Periodontal changes in children and adolescents with diabetes: a case-control study. Diabetes Care. 2006;29(2):295–9.
13. Ueta E, Osaki T, Yoneda K, Yamamoto T. Prevalence of diabetes mellitus in odontogenic infections and oral candidiasis: an analysis of neutrophil suppression. J Oral Path Med. 1999;24(1):168–74.
14. Salvi GE, Yadla B, Collins JG, Jones BH, Smith FW, Arnold RR, et al. Inflammatory mediator response as a potential risk marker for periodontal diseases in insulin-dependent diabetes mellitus patients. J Periodontol. 1997;68(2):127–35.
15. Al-Attas SA, Amro SO. Candidal colonization, strain diversity, and antifungal susceptibility among adult diabetic patients. Ann Saudi Med. 2010;30(2):101–8.
16. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9348):629–39.
17. Akpan A, Morgan R. Oral candidiasis. Postgrad Med J. 2002;78:455–9.
18. Scully C, El-Rahib M, Samaranayake LP. Candida and oral candidiasis: a review. CROBM. 1994;25(2):125–57.
19. Tarki BG. Oral candidiasis: aetiology, clinical manifestations, diagnosis and management. MÜSBED. 2011;1(2):140–8.
20. Olczak-Kowalczyk D, Gozdowski D, Grenda R, Pawłowska J, Górska R. Bistomycytom in pathological lesions on oral mucosa membrane in children and adolescents after transplant and with kidney or liver diseases. J Stoma. 2012;65(5):676–92.
21. Olczak-Kowalczyk D, Dąszkiewicz M, Kasaswa-Slawińska E, Dembowska-Baigińska B, Gozdowski D, Dąsiekiewicz P, et al. Bacteria and Candida yeasts in inflammations of the oral mucosa in children with secondary immunodeficiency. J Oral Pathol Med. 2012;41(7):568–76.
22. Vegeliak R, Nicolato O, Theodoridou M, Mostrou G, Legakis NJ. Paediatric AIDS - related linear gingival erythema: a form of erythematous candidiasis? J Oral Pathol Med. 1999;28(4):178–82.
23. Sots J, Rams TE, Listgarten MA. Yeasts, enteric rods and pseudomonads in the subgingival flora of severe adult periodontitis. Oral Microbiol Immunol. 1989;4:37–52.
24. Reynaud AH, Nygaard-Østby B, Baugard G, Erbe ER, Olsen I, Gjermo P. Yeasts in periodontal pockets. J Clin Periodontol. 2001;28:880–40.
25. Walsimo TM, Sen BH, Meurman JH, Örstavik D, Haapasalo MP. Yeasts in apical periodontitis. Curr Rev Oral Biol Med. 2003;1(4):138–39.
26. Akagawa G, Abe S, Yamaguchi H. Mortality of Candida albicans-infected mice is facilitated by superinfection of Escherichia coli or administration of its lipopolysaccharide. J Infect Dis. 1995;171:539–44.
27. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent Jr RL. Microbial complexes in subgingival plaque. J Clin Periodontol. 1998;25:134–44.
28. Tanam R, Sugamata M, Kiyoura Y. Candida albicans enhances invasion of human gingival epithelial cells and gingival fibroblasts by Porphyromonas gingivalis. Microb Pathol. 2011;51:250–4.
29. Mohan V, Ballal M. Proteinase and phospholipase activity as virulence factors in Candida species isolated from blood. Rev Iberoam Micol. 2008;25(4):208–10.
30. Schaller M, Borelli C, Korting HC, Hube B. Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses. 2005;48(6):365–77.
31. Naglik JR, Tischler E, Challacombe SJ. Candida secreted asparyl proteinases - expression and function during infection. Mikol Lek. 2004;11(1):139–44.
32. Huang G, Yi S, Sahn, N, Daniels KJ, Srikantha T, Scoll DR. N-acetylgalcosamine induces white to opaque switching, a mating prerequisite in Candida albicans: PLoS Pathog. 2010; 6(3). doi:10.1371/annotation/e4d41d73-c880-4e85-ad9f-7a390be268f6.
33. Kulaga Z, Różażyńska A, Palczewska I, Gądaja A, Gurtówka B, Napieralska E, et al. Grupa Badaczy OLAF. Siatki centylowe wysoko, masy ciała i wskaźniki masy ciała dzieci w Polsce – wyniki badania Olaf. Standardy Medyczne. 2010;6:690–700.
34. Samaranayake YH, Dassanayake RS, Jayatilake JA, Cheung BP, Yau JY, Yeung KW, et al. Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection. J Med Microbiol. 2005;54(P 6):583–93.
35. Kramer IR, Pindborg JJ, Beskouk V, Infirri JS. Guide to epidemiology and management. MÜSBED. 2011;1(2):140–8.
36. Reiss E, Morrison CJ. Nonculture methods for diagnosis of disseminated candidiasis. Clin Microbiol Rev. 1993;6(3):211–33.
years of age, healthy and with gingivitis. Acta Odontol Latinoam. 2011;24(2):176–82.

40. Pinson M, Hoffman WH, Garnick JJ, Litaker MS. Periodontal disease and type I diabetes mellitus in children and adolescents. J Clin Periodontol. 1995;22(2):118–23.

41. de Pommereau V, Dargent-Paré C, Robert JJ, Brion M. Periodontal status in insulin-dependent diabetic adolescents. J Clin Periodontol. 1992;19(9 Pt 1):528–32.

42. Saes Busato IM, Bittencourt MS, Machado MA, Grêgio AM, Azevedo-Elánis LR. Association between metabolic control and oral health in adolescents with type I diabetes mellitus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;109(3):e51–6. doi:10.1016/j.tripleo.2009.10.037.

43. Taylor G. Bi-directional interrelationships between diabetes and periodontal diseases: an epidemiologic perspective. Ann Periodontol. 2001;6:99–112.

44. Wood N, Johnson RB, Streckfus CF. Comparison of body composition and periodontal disease using nutritional assessment techniques: Third National Health and Nutrition Examination Survey (NHANES III). J Clin Periodontol. 2003;30:21–7.

45. Saito T, Shimazaki Y, Kyohara Y, Kato I, Kubo M, Iida M, et al. Relationship between obesity, glucose tolerance, and periodontal disease in Japanese women: the Hisayama study. J Periodontal Res. 2005;40:460–63.

46. Mérouani A, Lévy E, Mongeau JG, Robitaille P, Lambert M, Delvin EE. Hyperlipidemic profiles during remission in childhood idiopathic nephrotic syndrome. Clin Biochem. 2003;36(7):571–4.

47. Mahmoud S, Jahan S, Hossain MM. Hyperlipidemia in childhood idiopathic nephrotic syndrome during initial remission and relapse. Mymensingh Med J. 2011;20(3):402–6.

48. Plomer-Niezgoda E, Hrynczewicz-Gwoźdź A, Maj J, Baran E, Walów B. The estimation of the activity of hydrolytic exoenzymes and of susceptibility of the yeast-like fungi to antifungal agents in patients with CTCL and bullous diseases treated with immunosuppressive therapies. Mikol Lek. 2004;41(1):35–41.

49. Kurnatowska AJ, Kurnatowski P. Biotypes of fungi isolated from patients with oral cavity diseases. Mikol Lek. 1998;54(1):213–7.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit